

MatriSys Bioscience Announces Acquisition of Key Intellectual Property

The company dramatically expands its intellectual property portfolio and platform surrounding the use of microbiome-derived therapeutics for skin diseases


SAN DIEGO, CALIFORNIA, USA, March 29, 2018 /EINPresswire.com/ -- MatriSys Bioscience, a biopharmaceutical company located in La Jolla, California, specializing in the development and commercialization of microbiome-based therapeutics for the treatment of skin diseases, is pleased to announce today that it has acquired the rights to several additional US patents and patent filings relating to its microbiome-based technology.

MatriSys Bioscience has now completed a licensing agreement amendment with the University of California, San Diego for Intellectual Property covering 1) a Live Biotherapeutic product (Staphylococcus epidermidis strains M034 and M038 producing "Firmocidin") for protection against UV induced tumors and to potentially treat skin cancer, 2) a topical product for the treatment of Rosacea,

and 3) animal health rights for all IP licensed to date. The inventions were developed by UCSD Professor Richard L. Gallo who is a well-known pioneer in the use of microbiome-based therapeutics to treat skin disease and a co-founder of the company.

One of the patent filings acquired covers the use of Firmocidin, a small molecule DNA building block analog (nucleotide) produced by Staphylococcus epidermidis strains M034 and M038 with the capacity to inhibit DNA synthesis. Firmocidin suppresses growth of group A streptococcus (GAS), group B streptococcus (GBS) and Staphylococcus aureus (S. aureus) including MRSA, a bacterium that is highly resistant to antibiotics. When Firmocidin is administered intravenously or the live Staphylococcus epidermidis strains M034 and M038 are applied topically to mice with UV light exposure, Firmocidin suppressed tumor growth in vivo without evidence of systemic toxicity and reduced UV-induced pre-cancerous skin lesions formation.

Additionally, US patent # 9,801,848 acquired by MatriSys Bioscience involves the use of a small



molecule inhibitor of Trypsin-like serine proteases for the prevention of rosacea inflammation. Rosacea is one of the most common dermatological disorders as it is estimated that more than 16 million Americans experience rosacea. Clinical evidence directly supports a causative role for high protease activity in the pathogenesis of rosacea. Topical applications of a cream formulation that inhibits skin kallikreins has been shown in a limited clinical trial to result in a reduction of erythema and inflammatory papules in patients with rosacea.

The UCSD licensing agreement amendment additionally grants MatriSys exclusive rights to the veterinary uses of our core technology, US PCT US2016/031067. MatriSys sees an opportunity to capitalize on microbiome technology to improve current veterinary therapeutics. Our IP portfolio opens new avenues for treating infectious bacterial diseases which are a major cause of morbidity in animals. Infection-causing bacteria in animals also show trends of increasing resistance to a wide range of commonly used antimicrobial agents in veterinary care. MatriSys plans to develop a remedial treatment for cattle mastitis, an infection of the mammary gland that occurs most commonly in dairy and beef cows. Currently treated with antibiotics, *S. aureus* infections are the most commonly reported cause of mastitis in dairy-producing animals. Pyoderma in dogs (also known as "hot spots") is another common skin disorder often seen in veterinary practice. Bacterial infection occurs as the result of underlying conditions that make the dog more susceptible. Treating pyoderma in companion dogs requires chronic therapy due to similar etiology as atopic dermatitis in man.

"With the acquisition of these rights, we are substantially increasing our microbiome-based technology portfolio and now also extending our core technical development towards new product candidates for both the human and veterinary pharmaceutical markets" said Mark S. Wilson, Chief Executive Officer of MatriSys Bioscience.

About MatriSys Bioscience

MatriSys Bioscience is a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions. Our foundational microbiome therapeutics platform is based on the pioneering work of Richard L. Gallo MD PhD, Distinguished Professor and Founding Chair, Department of Dermatology at the University of California, San Diego and the <http://gallolab.ucsd.edu/>. For more information, please visit <http://www.matrisysbio.com/>.

###

Mark S. Wilson
MatriSys Bioscience, Inc.
(858) 456-3919
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.